EditorialEditorial
Open Access
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China
Jianbin Li and Zefei Jiang
Cancer Biology & Medicine October 2024, 21 (10) 838-843; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0374
Jianbin Li
1Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing 100071, China
2Department of Medical Molecular Biology, Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing 100071, China
Zefei Jiang
1Senior Department of Oncology, Fifth Medical Center of PLA General Hospital, Beijing 100071, China

References
- 1.↵
- 2.↵
- Li J,
- Zhou J,
- Wang H,
- Liu Z,
- Fan Z,
- Liu Y, et al.
- 3.↵
- Curigliano G,
- Burstein HJ,
- Gnant M,
- Loibl S,
- Cameron D,
- Regan MM, et al.
- 4.↵
- Shao Z,
- Pang D,
- Yang H,
- Li W,
- Wang S,
- Cui S, et al.
- 5.↵
- 6.↵
- 7.↵
- Ma F,
- Yan M,
- Li W,
- Ouyang Q,
- Tong Z,
- Teng Y, et al.
- 8.↵
- Yan M,
- Bian L,
- Hu X,
- Zhang Q,
- Ouyang Q,
- Feng J, et al.
- 9.↵
- Xu B,
- Yan M,
- Ma F,
- Hu X,
- Feng J,
- Ouyang Q, et al.
- 10.↵
- 11.↵
- 12.↵
- Jiang Z,
- Yu Z,
- Geng C,
- Lin Y,
- Liu Z,
- Fu P, et al.
- 13.↵
- He M,
- Hao S,
- Ma L,
- Xiu B,
- Yang B,
- Wang Z, et al.
- 14.↵
- 15.↵
- 16.↵
- 17.↵
- Rastogi P,
- O’Shaughnessy J,
- Martin M,
- Boyle F,
- Cortes J,
- Rugo HS, et al.
- 18.↵
- 19.↵
- Zhang QY,
- Sun T,
- Yin YM,
- Li HP,
- Yan M,
- Tong ZS, et al.
- 20.↵
- 21.↵
- Zhang P,
- Zhang Q,
- Tong Z,
- Sun T,
- Li W,
- Ouyang Q, et al.
- 22.↵
- 23.↵
- 24.↵
- 25.↵
- 26.↵
- 27.↵
- 28.↵
- Li J,
- Yuan Y,
- Bian L,
- Lin Q,
- Yang H,
- Ma L, et al.
In this issue
Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: International Contributions from China
Jianbin Li, Zefei Jiang
Cancer Biology & Medicine Oct 2024, 21 (10) 838-843; DOI: 10.20892/j.issn.2095-3941.2024.0374
Jump to section
- Article
- Human epidermal growth factor receptor 2 (HER2)-positive breast cancer: target drugs from meager-to-abundant
- Triple negative breast cancer (TNBC): the torchlight brought by immunotherapy
- Hormone receptor (HR)-positive breast cancer: comprehensive era of cyclin D kinase 4/6 (CDK4/6) inhibitors
- HER2 low-expression breast cancer: new field, new journey
- Conclusions
- Conflict of interest statement
- Author contributions
- References
- Figures & Data
- Info & Metrics
- References
Related Articles
- No related articles found.
Cited By...
- No citing articles found.